Replies to post #331574 on Avid Bioservices Inc (CDMO)

[biopharm]

Revs Guidance
(FY’20 fye 4-30-20): $64-67M. 7-31-19 Backlog=$61M
*Cash: 7-31-19: $28.9M
*As of 8-31-19: 56,237,674 shares o/s.

Attaching this to CJs post in case one wants to read the entire post...

....and to compare to 4-30-19 numbers... with a comment from Hancock that they reached cash flow positive during that fye

Revs Guidance
(FY’20 fye 4-30-20): $64-67M. 4-30-19
Backlog=$46M as of 4-30-19
*Cash: 4-30-19: $32.4M
*As of 6-14-19: 56,137,724 shares o/s.
...
...
Hancock:
"Most importantly, during Q4, the Company achieved positive income, generating cash from development & mfg. operations for the 1st time since the beginning of the transition.
..."